PIK3CA and female reproductive organ cancer: Outside of WX390, a 2024 prospective multicenter alpelisib program in PIK3CA-mutated gynecologic cancers (n = 36) reported ORR of 28% and DCR of 61% overall; the cohort included a small cervical subset but did not provide cervical-specific or HPV-stratified outcomes, nor PFS/OS estimates by histotype [120].